Somatostatin pp 337-341 | Cite as

Efficacy and Safety of a Somatostatin Analogue in Active Acromegaly

  • George Tolis
  • Angelos Yotis
  • Emilio del Pozo
  • Alan Harris
Chapter
Part of the Serono Symposia, USA book series (SERONOSYMP)

Abstract

Acromegaly has been associated, in the past, with chronic discomfort leading from invalidism to death. Partial or complete removal of the pituitary gland has been the preferred mode of therapy but if the growth hormone (GH) secreting tumor cannot be totally removed GH oversecretion will persist.

Keywords

Growth Hormone Carpal Tunnel Syndrome Pituitary Tumor Growth Hormone Secretion Acromegalic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984; 59: 1148–51.PubMedCrossRefGoogle Scholar
  2. 2.
    Lamberts SWJ, Verleun T, Oosterom R. The interrelationship between the effects of somatostatin and human pancreatic growth hormone-releasing factor on growth hormone release by cultured pituitary tumor cells from patients with acromegaly. J Clin Endocrinol Metab 1984; 58: 250–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Reubi JC, Perrin M, Rivier J, Vale W. Pituitary somatostatin receptors: dissociation at the pituitary level of receptor affinity and biological activity for selective somatostatin analogs. Regul Pept 1982; 4: 141–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Bauer W, Briner U, Doepfner W, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Plewe G, Beyer J, Krause W, Neufeld M, del Pozo E. Long-acting and selective suppression of GH secretion by SMS 201–995 in acromegaly. Lancet 1984; 2: 782–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Tolis G, Pitoulis C, Yotis A, et al. Therapy of acromegaly with a mini somatostatin. Program, Endocrine Society, 1984: 488.Google Scholar
  7. 7.
    Tolls G. SMS 201–995: long term use in active acromegaly. Neuro-endocrinology Letters 1985; 7: 119.Google Scholar
  8. 8.
    CH’NG, LJC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR. Long term treatment of acromegaly with a long acting analogue of somatostatin. Br Med J 1985; 290: 284–5.CrossRefGoogle Scholar
  9. 9.
    Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. The somatostatin analogue SMS 201–995 induces long-acting inhibition of GH secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60: 1161–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Lamberts SWJ, Vitterlinden P, Verschoorm L, Van Dongen KT, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 1985; 313: 1576–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Tolls G, Malachtari S, Mortoglou A, et al. Therapy of acromegaly with SMS 201–995: long-term studies. Scand J Gastroenterol 1986 (in press).Google Scholar
  12. 12.
    Tolls G, Yotis A, del Pozo E, Pitoulis S. Long-term therapeutic efficacy of a somatostatin analogue (SMS 201–995) in active acromegaly. J Neurosurg 1986 (in press).Google Scholar
  13. 13.
    Tolls G, Yotis A, Malachtari S, et al. Follow-up of acromegalic patients treated with an octapeptide somatostatin analogue for over a year. Program, Endocrine Society Annual Meeting, 1986.Google Scholar
  14. 14.
    del Pozo E, Kutz K. Pharmacological properties and effects on glucose homeostasis of a somatostatin derivative (SMS 201–995): studies in human. In: Ludecke D, Tolls G, eds. Growth hormone and acromegaly. New York: Raven Press, 1986 (in press).Google Scholar
  15. 15.
    Reubi JC. Evidence for two somatostatin-14-receptor types in rat brain cortex. Neurosci Lett 1984; 49: 259–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Maurer R, Gaehwiler BH, Buescher HH, Hill RC, Roemer D. Opiate antagonistic properties of an octapeptide somatostatin analog. Proc Natl Acad Sci USA 1982; 79: 4815–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Kiang JG, Wei ET. Inhibition of an opioid-evoked vagal reflex in rats by naloxone, SMS 201–995 and ICI 154, 129. Regul Pept 1983; 6: 255–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Beal MF, Martin JB. The effect of somatostatin on striatal catecholamines. Neurosci. Lett 1984; 44: 271–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • George Tolis
    • 1
    • 2
  • Angelos Yotis
    • 1
    • 2
  • Emilio del Pozo
    • 1
    • 2
  • Alan Harris
    • 1
    • 2
  1. 1.Hippokrateion HospitalAthensGreece
  2. 2.Clinical ResearchSandoz Ltd.BasleSwitzerland

Personalised recommendations